Loading…
Chinese biopharma known for diagnostic reagents and vaccines, including its homegrown HPV vaccine and infectious-disease test kits.
Chinese biopharma known for diagnostic reagents and vaccines, including its homegrown HPV vaccine and infectious-disease test kits.
Earns from two different businesses: vaccines, sold in China largely to provincial disease-control centres that supply community clinics where people pay out of pocket, and diagnostic kits sold to hospitals and labs through distributors. Its Innovax subsidiary makes the HPV vaccine, which the WHO pre-qualified in 2021, a step toward supply to international buyers.
In one line: A Chinese hybrid of a diagnostics maker and an HPV vaccine developer.
Moat: narrow (IP / patents, regulatory licence, brand). First Chinese maker of a homegrown 9-valent HPV vaccine, plus an established diagnostics franchise.
Headquarters: Beijing, China · Employees: 4,116
Size Beijing Wantai Biological Pharmacy Enterprise (603392.SS) is a China Health Care company (Biotechnology) with a market value of $4.72B, the 533rd largest of 4,839 China companies the cockpit tracks. Shares closed at CN¥24.90 on 6 Nov 2026.
Performance Over six months the shares fell 36.6%, against -1.2% for the median peer and -16.4% for the China market (cap-weighted) — lowest of 21 in its peer set.
Growth Revenue grew 8.3% over the last twelve months (peer median +11.5%); the operating margin is -35.0% (peer median -11.8%).
Valuation It trades at 14.5× enterprise value to sales against a peer median of 14.7× (8th cheapest of 16).
Capital Return on invested capital runs 11.2 points below its cost of capital (7.8% WACC).
Next results Next results expected around 25 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥1.94B | CN¥1.81B | CN¥2.24B | CN¥5.49B | CN¥11.1B |
| Revenue growth | — | -19% | -59% | -51% | — |
| Gross profit | CN¥1.27B | CN¥690M | CN¥1.24B | CN¥4.43B | CN¥9.86B |
| EBITDA | n/a | -CN¥375M | -CN¥9.47M | CN¥1.62B | CN¥5.42B |
| Net income | -CN¥456M | -CN¥398M | CN¥106M | CN¥1.25B | CN¥4.74B |
| Free cash flow | -CN¥457M | -CN¥601M | -CN¥389M | CN¥444M | CN¥3.21B |
| Capital expenditure | CN¥599M | CN¥805M | CN¥887M | CN¥1.16B | CN¥930M |
| Total debt | CN¥364M | CN¥374M | CN¥407M | CN¥399M | CN¥313M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g |
|---|---|---|---|---|---|---|
| Beijing Wantai Biological Pharmacy Enterprise 603392.SS | $4.72B | -37% | +8% | -35% | 14.5× | n/a |
| Chongqing Zhifei Biological Products 300122.SZ | $5.35B | -2% | -28% | -210% | 5.4× | -6.4% |
| Merck & MRK | $362B | +33% | +5% | 18% | 5.4× | 4.1% |
| Shenzhen Kangtai Biological Products 300601.SZ | $2.11B | -9% | -9% | 6% | 5.6× | 25.3% |
| Innovita Biological Technology 688253.SS | $1.02B | -4% | -28% | 11% | 16.3× | 42.9% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 603392.SS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -6.0% | +3.8% | 3rd lowest of 21 |
| 6-month return | -36.6% | -1.2% | lowest of 21 |
| Distance from 52-week high | -57.5% | -23.5% | lowest of 21 |
| Revenue growth (TTM) | +8.3% | +11.5% | 8th lowest of 16 |
| Operating margin | -35.0% | -11.8% | 8th lowest of 16 |
| EV / Sales | 14.5× | 14.7× | 8th cheapest of 16 |
| ROIC minus cost of capital | -11.2 pp | -10.6 pp | 7th lowest of 14 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Beijing Wantai Biological Pharmacy Enterprise 603392.SS | China | $4.72B | -37% | +8% | -35% | 14.5× | n/a | n/a |
| Dianthus Therapeutics DNTH | United States | $4.81B | -1% | -61% | -11,441% | 2,087.9× | n/a | n/a |
| CRISPR Therapeutics CRSP | United States | $4.86B | -9% | -34% | -2,059% | 133.6× | n/a | n/a |
| Joinn Laboratories (China) 603127.SS | China | $4.58B | +15% | +12% | -4% | 15.1× | n/a | n/a |
| Shanghai RAAS Blood Products 002252.SZ | China | $4.89B | -11% | -22% | 17% | 5.7× | n/a | n/a |
| Edgewise Therapeutics EWTX | United States | $4.89B | +28% | n/a | n/a | n/a | n/a | n/a |
| 3SBio 1530.HK | Hong Kong | $4.92B | -34% | +102% | 61% | 1.2× | n/a | n/a |
| Changchun High-Tech Industry (Group) 000661.SZ | China | $4.51B | -13% | -18% | -1% | 2.8× | 32.2% | +7.1% |
| Adaptive Biotechnologies ADPT | United States | $4.47B | +103% | +50% | -12% | 14.7× | n/a | n/a |
| Chongqing Zhifei Biological Products 300122.SZ | China | $5.35B | -2% | -28% | -210% | 5.4× | -6.4% | -10.0% |
| Anthem Biosciences ANTHEM.NS | India | $5.46B | +17% | -1% | 35% | 24.9× | 36.7% | +26.2% |
| Relay Therapeutics RLAY | United States | $4.08B | +46% | +24% | -2,999% | 308.8× | n/a | n/a |
| Cogent Biosciences COGT | United States | $5.49B | -9% | n/a | n/a | n/a | n/a | n/a |
| Hangzhou Tigermed Consulting 300347.SZ | China | $5.58B | -6% | +16% | 10% | 5.4× | 28.4% | +16.4% |
| Scholar Rock SRRK | United States | $5.72B | -3% | n/a | n/a | n/a | n/a | n/a |
| AbCellera Biologics ABCL | United States | $3.85B | +149% | +101% | -340% | 51.7× | n/a | n/a |
| Beijing Tiantan Biological Products 600161.SS | China | $3.76B | -11% | -13% | 21% | 4.8× | 3.2% | +12.5% |
| Lin BioScience 6696.TWO | Taiwan | $3.74B | +129% | n/a | n/a | n/a | n/a | n/a |
| Iovance Biotherapeutics IOVA | United States | $3.64B | +64% | +35% | -91% | 10.4× | n/a | n/a |
| Tango Therapeutics TNGX | United States | $3.63B | -7% | +121% | -253% | 49.1× | n/a | n/a |
| Enliven Therapeutics ELVN | United States | $3.62B | +21% | n/a | n/a | n/a | n/a | n/a |